With, collectively, over 70 years experience in the Drug Discovery environment we are confident our team can fulfil your needs for any part of the Gene to Structure process.
We tailor our professional services to fit your requirements, whatever stage of the process you are at.
From construct design, through to expression and purification of your desired protein. Whatever your end use, assay, high throughput screening, biophysics or crystallisation and X-ray structure determination, we can supply your protein in a suitable format.
For NMR experiments, we can produce isotopically labelled proteins e.g. 15N and 13C. For de novo structure solution we are equipped to produce SeMet labelled protein.
Peak Proteins’ Services
Image kindly supplied by Oxford Expression Technologies
Protein Expression and Production
We are able to model and engineer a target protein using a variety of software and bioinformatic packages in order to maximise success for a range of different final uses such as screening, different types of structural biology, biophysics and in vivo studies.
X-ray crystallography can reveal details of protein-ligand interactions at the molecular level. We have the facilities and knowledge to crystallise your chosen protein and solve the structure if desired.
Skilled management of multiple projects ensures a careful balancing of rapid quick turn-around pieces with long-term involvement.
As a team
we are accountable for delivery
we offer innovative solutions to drive project progression
we apply collaborative problem solving
we have experience of multiple classes of protein for a wide range of end uses
It is our aim
To keep you informed of the progress at all stages of the project. A central project contact will initiate a start-up meeting, supply regular updates and co-ordinate meetings to discuss progress. Most importantly, we want you to consider us approachable and available to discuss progress, hurdles and any questions at any time, along the way.
The team at a glance
Mark Abbott PhD Protein expression and purification specialist
August 17th, 2016|Comments Off on FEN1-inhibitor co-crystal structure published
Mark Abbott has recently co-authored a paper in Nature Chemical Biology as part of a collaboration between AstraZeneca, University of Sheffield and Pelago BioSciences. The publication describes the co-crystal structure of […]
January 27th, 2016|Comments Off on Sygnature Discovery’s group invests in Peak Proteins
Nottingham, UK and Alderley Park, UK – 25th January 2016 – Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise has invested, through its parent […]